FX-322 in Adults With Acquired Sensorineural Hearing Loss
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05086276 |
|
Recruitment Status :
Completed
First Posted : October 20, 2021
Results First Posted : April 21, 2023
Last Update Posted : April 21, 2023
|
Sponsor:
Frequency Therapeutics
Information provided by (Responsible Party):
Frequency Therapeutics
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hearing Loss, Sensorineural Noise Induced Hearing Loss Sudden Hearing Loss | Drug: FX-322 Drug: Placebo | Phase 2 |
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).
Previous human studies in subjects 18 to 65 years inclusive (FX-322-103, FX-322-201, FX-322-111) and subjects 66-85 inclusive (FX-322-112) demonstrated that a single dose FX-322 was well tolerated in patients with acquired SNHL with no treatment-related serious adverse events. Adverse events in these studies were generally common to and associated with the intratympanic injection procedure with mild and transient discomfort in patients both with the drug and the placebo.
Frequency Therapeutics' Investigators intend to evaluate efficacy with a single dose of FX-322 in subjects 18 to 65 years inclusive with acquired SNHL.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 142 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss |
| Actual Study Start Date : | October 12, 2021 |
| Actual Primary Completion Date : | December 30, 2022 |
| Actual Study Completion Date : | December 30, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Hearing Disorders and Deafness
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: FX-322
FX-322, 1 dose
|
Drug: FX-322
Active Comparator |
|
Placebo Comparator: Placebo
Placebo, 1 dose
|
Drug: Placebo
Placebo |
Primary Outcome Measures :
- Word Recognition in Quiet [ Time Frame: Baseline through Day 90 ]Percent of subjects exceeding the Carney-Schlauch 95% confidence interval for improvement from baseline in number of words recognized from Consonant-Nucleus-Consonant (CNC) word lists
Secondary Outcome Measures :
- Words-in-Noise [ Time Frame: Baseline through Day 90 ]Mean absolute percent change in number of recognized words from CNC word lists
- Standard Pure Tone Audiometry [ Time Frame: Baseline through Day 90 ]Mean overall pure tone average (PTA) hearing thresholds in decibels (dB) derived by averaging the air conduction thresholds at 0.5, 1, 2 and 4 kHZ frequencies
- Patient Global Impression of Change (PGI-C) Hearing Loss Scale [ Time Frame: Day 90 ]Average response in PGI-C hearing loss scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse
- Patient Global Impression of Change (PGI-C) Daily Impacts Scale [ Time Frame: Day 90 ]Average response in PGI-C daily impacts scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject has read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure.
- Adult aged 18-65 years inclusive at Screening.
- Documented medical history consistent with acquired, adult onset, sensorineural hearing loss associated with noise-induced SNHL (NIHL) or idiopathic sudden SNHL (SSNHL) (documented audiogram at least 6 months prior to screening required).
- A pure tone average at the Screening Visit of 35-85 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the ear to be injected.
- Ability to communicate well with the Investigator and is willing to comply with and complete all the study procedures.
- Female subjects must be of non-childbearing potential or will need to utilize two methods of highly effective contraception during the study participation (e.g. hormonal contraception and condom or an intrauterine device and condom) or remain abstinent. Male subjects should use condoms with spermicide during the course of the study or remain abstinent. Subjects should not donate sperm or ova during the study period.
- Have met additional masked criteria as determined by the Electronic Data Capture system.
Exclusion Criteria:
- Subject has previously been randomized in a FX-322 clinical trial.
- Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.
- Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10dB at two or more contiguous octave frequencies in the study ear at the Screening visit.
- Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.
- Subject has had an intratympanic injection in either ear within 3 months of the screening visit.
- Evidence of or previous diagnosis of auditory neuropathy, traumatic brain injury, "central" hearing loss, or genetic hearing loss.
- History of chronic, recurrent clinically significant vestibular symptoms.
- History of bilateral sudden sensorineural hearing loss or recurrent sudden sensorineural hearing loss.
- History of clinically significant systemic autoimmune disease (e.g. rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).
- History of head or neck radiation, treatment, or exposure to platinum based chemotherapy drugs or aminoglycosides.
- Exposure to another investigational drug within 28 days prior to screening visit.
- Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).
- Positive urine pregnancy test or breast-feeding.
- Any known factor, condition, or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05086276
Locations
| United States, Arizona | |
| Clinical Trial Site | |
| Tucson, Arizona, United States, 00000 | |
| United States, California | |
| Clinical Trial Site | |
| Fresno, California, United States, 00000 | |
| Clinical Trial Site | |
| Torrance, California, United States, 00000 | |
| United States, Colorado | |
| Clinical Trial Site | |
| Colorado Springs, Colorado, United States, 00000 | |
| United States, Florida | |
| Clinical Trial Site | |
| Sarasota, Florida, United States, 00000 | |
| Clinical Trial Site | |
| Tampa, Florida, United States, 00000 | |
| United States, Louisiana | |
| Clinical Trial Site | |
| Marrero, Louisiana, United States, 00000 | |
| United States, Michigan | |
| Clinical Trial Site | |
| Novi, Michigan, United States, 00000 | |
| United States, Nebraska | |
| Clinical Trial Site | |
| Omaha, Nebraska, United States, 00000 | |
| United States, New York | |
| Clinical Trial Site | |
| Albany, New York, United States, 00000 | |
| Clinical Trial Site | |
| Amherst, New York, United States, 00000 | |
| Clinical Trial Site | |
| New York, New York, United States, 00000 | |
| United States, North Carolina | |
| Clinical Trial Site | |
| Winston-Salem, North Carolina, United States, 00000 | |
| United States, Ohio | |
| Clinical Trial Site | |
| Cincinnati, Ohio, United States, 00000 | |
| United States, Oklahoma | |
| Clinical Trial Site | |
| Oklahoma City, Oklahoma, United States, 00000 | |
| United States, South Carolina | |
| Clinical Trial Site | |
| Charleston, South Carolina, United States, 00000 | |
| Clinical Trial Site | |
| Orangeburg, South Carolina, United States, 00000 | |
| Clinical Trial Site | |
| Spartanburg, South Carolina, United States, 00000 | |
| United States, Texas | |
| Clinical Trial Site | |
| Dallas, Texas, United States, 00000 | |
| Clinical Trial Site | |
| Fort Worth, Texas, United States, 00000 | |
| Clinical Trial Site | |
| San Antonio, Texas, United States, 00000 | |
| United States, Utah | |
| Clinical Trial Site | |
| Murray, Utah, United States, 00000 | |
| Clinical Trial Site | |
| Saint George, Utah, United States, 00000 | |
| United States, Virginia | |
| Clinical Trial Site | |
| Norfolk, Virginia, United States, 00000 | |
| Clinical Trial Site | |
| Richmond, Virginia, United States, 00000 | |
| United States, Wisconsin | |
| Clinical Trial Site | |
| Milwaukee, Wisconsin, United States, 00000 | |
Sponsors and Collaborators
Frequency Therapeutics
Investigators
| Study Director: | Carl LeBel, PhD | Frequency Therapeutics |
Study Documents (Full-Text)
Documents provided by Frequency Therapeutics:
Documents provided by Frequency Therapeutics:
Study Protocol [PDF] January 5, 2022
Statistical Analysis Plan [PDF] January 19, 2023
| Responsible Party: | Frequency Therapeutics |
| ClinicalTrials.gov Identifier: | NCT05086276 |
| Other Study ID Numbers: |
FX-322-208 |
| First Posted: | October 20, 2021 Key Record Dates |
| Results First Posted: | April 21, 2023 |
| Last Update Posted: | April 21, 2023 |
| Last Verified: | April 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Frequency Therapeutics:
|
Intratympanic administration Restoration of hearing loss |
Additional relevant MeSH terms:
|
Hearing Loss Deafness Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss, Sudden Hearing Disorders |
Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |